托珠单抗调节院外心脏骤停后全身炎症反应的研究方案
本研究为研究者发起的双盲、安慰剂对照、单中心随机临床试验,计划纳入80例因推测心脏原因导致院外心脏骤停后持续昏迷的成人患者,按1:1随机接受单次1小时静脉输注托珠单抗或安慰剂(氯化钠)。主要终点为C反应蛋白(CRP)的降低,次要终点包括细胞因子水平、脑/心/肾/肝损伤标志物、血流动力学与止血功能、不良事件及随访脑功能与死亡率。研究假设通过阻断IL-6受体减轻全身炎症反应,从而改善心脏骤停后综合征的严重程度。
要点
- 纳入院外心脏骤停后持续昏迷的成人患者,推测心脏原因,年龄≥18岁。
- 80例患者1:1随机接受单次1小时静脉输注托珠单抗或安慰剂(氯化钠)。
- 主要终点为CRP降低,次要终点涵盖细胞因子、器官损伤标志物及临床结局。
核心结论
- 研究假设阻断IL-6受体可减轻院外心脏骤停后全身炎症反应,进而减轻心脏骤停后综合征严重程度。
研究设计与样本
- 研究者发起的双盲、安慰剂对照、单中心随机临床试验。
- 计划纳入80例院外心脏骤停后持续昏迷的成人患者,按1:1随机分组。
- 干预为单次1小时静脉输注托珠单抗或安慰剂(氯化钠),期间均接受标准治疗。
关键数值与推荐
- 主要终点:C反应蛋白(CRP)的降低。
- 次要终点包括细胞因子水平、脑/心/肾/肝损伤标志物、血流动力学与止血功能、不良事件及随访脑功能与死亡率。
- 标准治疗包括镇静、至少24小时目标温度管理36°、按需使用血管升压药和/或正性肌力药、预防性抗生素及医生酌情追加治疗。
临床怎么用
- 该方案尚处于研究阶段,托珠单抗用于院外心脏骤停后抗炎治疗的安全性与有效性需待试验结果验证。
局限性
- 单中心设计可能限制结果外推性。
- 样本量80例,研究把握度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resuscitated out-of-hospital cardiac arrest (OHCA) patients who remain comatose at admission are at high risk of morbidity and mortality. This has been attributed to the post-cardiac arrest syndrome (PCAS) which encompasses multiple interacting components, including systemic inflammation. Elevated levels of circulating interleukin-6 (IL-6), a pro-inflammatory cytokine, is associated with worse outcomes in OHCA patients, including higher vasopressor requirements and higher mortality rates. In this study, we aim to reduce systemic inflammation after OHCA by administering a single infusion of tocilizumab, an IL-6 receptor antibody approved for use for other indications. METHODS: Investigator-initiated, double-blinded, placebo-controlled, single-center, randomized clinical trial in comatose OHCA patients admitted to an intensive cardiac care unit. Brief inclusion criteria: OHCA of presumed cardiac cause, persistent unconsciousness, age ≥ 18 years. INTERVENTION: 80 patients will be randomized in a 1:1 ratio to a single 1-h intravenous infusion of either tocilizumab or placebo (NaCl). During the study period, patients will receive standard of care, including sedation and targeted temperature management of 36 ° for at least 24 h, vasopressors and/or inotropes as/if needed, prophylactic antibiotics, and any additional treatment at the discretion of the treating physician. Blood samples are drawn for measurements of biomarkers included in the primary and secondary endpoints during the initial 72 h. Primary endpoint: reduction in C-reactive protein (CRP). Secondary endpoints (abbreviated): cytokine levels, markers of brain, cardiac, kidney and liver damage, hemodynamic and hemostatic function, adverse events, and follow-up assessment of cerebral function and mortality. DISCUSSION: We hypothesize that reducing the effect of circulating IL-6 by administering an IL-6 receptor antibody will mitigate the systemic inflammatory response and thereby modify the severity of PCAS, in turn leading to lessened vasopressor use, more normal hemodynamics, and better organ function. This will be assessed by primarily focusing on hemodynamics and biomarkers of organ damage during the initial 72 h. In addition, pro-inflammatory and anti-inflammatory cytokines will be measured to assess if cytokine patterns are modulated by IL-6 receptor blockage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03863015 ; submitted February 22, 2019, first posted March 5, 2019. EudraCT: 2018-002686-19; date study was authorized to proceed: November 7, 2018.
引用
- Meyer MAS, Wiberg S, Grand J, et al. Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest (IMICA): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. Trials. 2020. PMID: 33081828. doi:10.1186/s13063-020-04783-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。